Transcode Therapeutics, Inc. (RNAZ) has 7 open-market insider trades by 2 insiders since 2022. The most active filer is Robert Michael Dudley, CEO.
| Name | Title | Tier | Trades | Value | Last Trade |
|---|---|---|---|---|---|
| Robert Michael Dudley | CEO | — | 5 | $282K | 2023-09-28 |
| Thomas A. Fitzgerald | CFO | — | 2 | $40K | 2023-09-28 |
| Insider | Title | Type | Value | Date |
|---|---|---|---|---|
| Robert Michael Dudley | CEO | Buy | $50K | 2023-09-28 |
| Thomas A. Fitzgerald | CFO | Buy | $25K | 2023-09-28 |
| Robert Michael Dudley | CEO | Buy | $49K | 2023-06-20 |
| Robert Michael Dudley | CEO | Buy | $105K | 2023-06-09 |
| Robert Michael Dudley | CEO & 10% | Buy | $23K | 2022-09-14 |
| Thomas A. Fitzgerald | CFO | Buy | $15K | 2022-06-16 |
Companies that share insiders with RNAZ, and sector peers with recent insider buying. Related by who files, not by how the stocks move.
| Robert Michael Dudley | CEO | Buy | $55K | 2022-05-27 |